Biologics in vasculitides: Where do we stand, where do we go from now?

Giulia Pazzola; Francesco Muratore; Nicolò Pipitone; Carlo Salvarani

doi:10.1016/j.lpm.2015.04.010

Biologics in vasculitides: Where do we stand, where do we go from now?

Giulia Pazzola, Francesco Muratore, Nicolò Pipitone, Carlo Salvarani

Arcispedale Santa Maria Nuova

Research output: Contribution to journal › Article

Abstract

Biological agents represent a valid therapeutic option in patients with severe and/or relapsing vasculitis. Over the last years, some of these agents have become an established therapy (such as RTX in AAV or IFX for ocular BD), and some appear to hold promise to become so. In addition, there are a number of drugs in the pipeline that may contribute to further improve the prognosis of vasculitis. As the range of medications available for vasculitis widens, the need will also increase to define the best treatment schemes as well as to identify those patients that may benefit most from biological agents.

Original language	English
Pages (from-to)	e231-e239
Journal	Presse medicale (Paris, France : 1983)
Volume	44
Issue number	6
DOIs	https://doi.org/10.1016/j.lpm.2015.04.010
Publication status	Published - Jun 1 2015

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/j.lpm.2015.04.010

Fingerprint Dive into the research topics of 'Biologics in vasculitides: Where do we stand, where do we go from now?'. Together they form a unique fingerprint.

Cite this

Pazzola, G., Muratore, F., Pipitone, N., & Salvarani, C. (2015). Biologics in vasculitides: Where do we stand, where do we go from now? Presse medicale (Paris, France : 1983), 44(6), e231-e239. https://doi.org/10.1016/j.lpm.2015.04.010

@article{1ebc02901dbd485b81349ecccb3bcbeb,

title = "Biologics in vasculitides: Where do we stand, where do we go from now?",

abstract = "Biological agents represent a valid therapeutic option in patients with severe and/or relapsing vasculitis. Over the last years, some of these agents have become an established therapy (such as RTX in AAV or IFX for ocular BD), and some appear to hold promise to become so. In addition, there are a number of drugs in the pipeline that may contribute to further improve the prognosis of vasculitis. As the range of medications available for vasculitis widens, the need will also increase to define the best treatment schemes as well as to identify those patients that may benefit most from biological agents.",

author = "Giulia Pazzola and Francesco Muratore and Nicol{\`o} Pipitone and Carlo Salvarani",

year = "2015",

month = jun,

day = "1",

doi = "10.1016/j.lpm.2015.04.010",

language = "English",

volume = "44",

pages = "e231--e239",

journal = "Nouvelle Presse Medicale",

issn = "0755-4982",

publisher = "Elsevier Masson",

number = "6",

}

TY - JOUR

T1 - Biologics in vasculitides

T2 - Where do we stand, where do we go from now?

AU - Pazzola, Giulia

AU - Muratore, Francesco

AU - Pipitone, Nicolò

AU - Salvarani, Carlo

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Biological agents represent a valid therapeutic option in patients with severe and/or relapsing vasculitis. Over the last years, some of these agents have become an established therapy (such as RTX in AAV or IFX for ocular BD), and some appear to hold promise to become so. In addition, there are a number of drugs in the pipeline that may contribute to further improve the prognosis of vasculitis. As the range of medications available for vasculitis widens, the need will also increase to define the best treatment schemes as well as to identify those patients that may benefit most from biological agents.

AB - Biological agents represent a valid therapeutic option in patients with severe and/or relapsing vasculitis. Over the last years, some of these agents have become an established therapy (such as RTX in AAV or IFX for ocular BD), and some appear to hold promise to become so. In addition, there are a number of drugs in the pipeline that may contribute to further improve the prognosis of vasculitis. As the range of medications available for vasculitis widens, the need will also increase to define the best treatment schemes as well as to identify those patients that may benefit most from biological agents.

UR - http://www.scopus.com/inward/record.url?scp=84930870876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930870876&partnerID=8YFLogxK

U2 - 10.1016/j.lpm.2015.04.010

DO - 10.1016/j.lpm.2015.04.010

M3 - Article

AN - SCOPUS:84930870876

VL - 44

SP - e231-e239

JO - Nouvelle Presse Medicale

JF - Nouvelle Presse Medicale

SN - 0755-4982

IS - 6

ER -